StockTipsArenaBeta

BUY Zydus Lifesciences Limited — Rajesh Satpute

BUYZydus Lifesciences Limited
Zydus Lifesciences share price target & all analyst calls

byRajesh SatputeHorizon: Swing (≤2wk)30 Oct 2026via CNBC Awaaz.

Entry₹1,250Inferred
Target₹1,280
Total upside +2.40% (call closed)
Stop loss₹1,230-1.60% risk
Exit₹1,2303 Nov 2026, 9:20 am
Stop-loss hit-1.60%
Follow Rajesh Satpute for new calls(33% target hit, 215 closed calls)Get alertsWatch ZYDUSLIFE for new buy/sell callsGet alertsSee 204 active Swing picks this week

Not investment advice; past performance doesn't guarantee future results. · Public beta — data is auto-extracted and may contain errors.

AI Assessment

Automated market context for this BUY call — facts from public sources, machine-classified. Not investment advice.

Frozen at close · 3 Nov 2026
5 supporting1 opposing
Supports the BUY call (5)

Zydus Lifesciences has completed the acquisition of the API business of Sterling Biotech Limited.

BSE · Company Update·2 Nov · today

(opens in new tab)

1 advisor has an active short-term BUY call on this stock, issued in the last 14 days

Advisor consensus · adjacent horizon·28 Oct · 5d ago

Zydus Lifesciences' subsidiary Zylidac Bio has partnered with Prolific Machines to scale a biologics manufacturing platform to GMP production.

BSE · Company Update·21 Oct · 2w ago

(opens in new tab)

Zydus Lifesciences received USFDA approval for Estradiol and Levonorgestrel Transdermal System, qualifying for 180-day competitive generic therapy exclusivity.

BSE · Company Update·21 Oct · 2w ago

(opens in new tab)

Zydus Lifesciences received USFDA approval for its Estradiol and Levonorgestrel Transdermal System, qualifying for 180-day competitive generic therapy exclusivity.

NSE · Press Release·21 Oct · 2w ago

(opens in new tab)
Neutral / worth noting (0)

Nothing found in this tip’s window yet.

Weighs against the BUY call (1)

Zydus Lifesciences In Focus As US FDA Flags Data Integrity, Quality Control Issues At Gujarat Plant

NewsNdtv-Profit·26 Oct · 1w ago

(opens in new tab)

Factor classifications are AI-generated from exchange filings, verified news feeds and market data — they can be wrong or incomplete, and are not attributed to the issuing analyst. Verify every factor via its linked original before acting. This is not investment advice.

Other calls on Zydus Lifesciences

All analyst calls on Zydus Lifesciences

More from Rajesh Satpute

Every call and its outcome